Study to investigate safety, tolerability and pharmacokinetics of AZD2423 multiple doses in healthy volunteers
Study identifier:D2600C00002
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral AZD2423 Solution after Multiple Ascending Doses in Young and Elderly Healthy Volunteers
Medical condition
Healthy
Phase
Phase 1
Healthy volunteers
Yes
Study drug
Part 1 - AZD2423 or Placebo, Part 2 - AZD2423, Part 3 - AZD2423
Sex
All
Actual Enrollment
74
Study type
Interventional
Age
20 Years - 80 Years
Date
Study Start Date: 01 Oct 2009
Primary Completion Date: 01 May 2010
Study Completion Date: 01 May 2010
Study design
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Basic Science
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: Part 1 AZD2423 or Placebo AZD2423 or Placebo Oral Solution, multiple dosing during 10-14 days | Drug: Part 1 - AZD2423 or Placebo AZD2423 Oral Solution, multiple dosing during 10-14 days or Placebo Oral Solution, multiple dosing during 10-14 days |
| Experimental: Part 2 - AZD2423 AZD2423 Oral solution, multiple dosing | Drug: Part 2 - AZD2423 AZD2423 Oral solution, multiple dosing |
| Experimental: Part 3 - AZD2423 AZD2423 Oral solution single dosing or AZD2423 Oral solution, single dosing - With Food or AZD2423 Oral solution, single dosing - Fasting Condition. | Drug: Part 3 - AZD2423 AZD2423 Oral solution, single dosing or AZD2423 Oral solution, single dosing - With Food or AZD2423 Oral solution, single dosing - Fasting Condition. |
Contacts
Investigators
Principal Investigator
Dr Muna Albayaty
PAREXEL Early Phase Clinical Uniit, London
